Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
Palabras clave :
Heart failure
Spironolactone
Atrial remodelling
Collagen cross-linking
Fecha de publicación :
2022
Nota:
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License
Cita:
Ravassa, S. (Susana); López, B. (Begoña); Ferreira, J.P. (João Pedro); et al. "Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial". European Journal of Heart Failure. (24), 2022, 321 - 331
Aparece en las colecciones:
Estadísticas e impacto
0 citas en
0 citas en
Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.